TAK News and Press, Takeda Pharmaceutical Company Limited American Depositary Shares From 07/31/23

2023-07-31 09:00:00 ET Summary ASKA Pharmaceuticals' market cap is covered 30% by net non-operating assets that render its EV/EBITDA multiple too low for a growing generics business in Japan. It has a growing exposure to gynecological drugs, which in some cases are receiving benef...

2023-07-27 09:27:02 ET Takeda Pharmaceutical Company Limited (TAK) Q1 2023 Results Earnings Conference Call July 27, 2023, 06:00 AM ET Company Participants Christopher O'Reilly - Head, Investor Relations Christophe Weber - President and Chief Executive Officer An...

2023-07-27 06:45:10 ET Takeda Pharmaceutical press release ( NYSE: TAK ): Q1 GAAP EPS of ¥150.00 Revenue of ¥1.06T (+8.9% Y/Y). Revenue Growth of +8.9% at Actual Exchange Rate ( AER ); +3.7% Growth at Constant Exchange Rate (CER), Driven by Grow...

No Change to Full-Year Forecasts or Management Guidance Revenue Growth of +8.9% at Actual Exchange Rate (AER); +3.7% Growth at Constant Exchange Rate (CER), Driven by Growth & Launch Products (+16.2% at CER) Reported Operating Profit Growth of +12.0% at AER; Core Opera...

Trial Was Stopped Due to Hepatotoxicity and Consequently TAK-994 Program Terminated for Further Development In Patients with Narcolepsy Type 1, Oral Orexin Receptor 2 Agonist Demonstrated Statistically Significant Improvement in Daytime Wakefulness; Weekly Cataplexy Rates Reduced ...

2023-07-25 15:23:05 ET Aeglea BioTherapeutics ( NASDAQ: AGLE ) traded higher on Tuesday after Stifel launched its coverage with a Buy recommendation citing its potential against inflammatory bowel disorders, ulcerative colitis, and Crohn's disease. Despite rising competition amo...

2023-07-23 04:43:02 ET Summary Shares of precision oncology concern Day One Biopharmaceuticals, Inc. are down over 50% from their 2023 high as Novartis’ combination therapy received first approval for pLGG. However, its lead candidate (tovorafenib) has the potential to trea...

2023-07-17 15:06:06 ET Summary Turnstone Biologics Corp. has filed proposed terms for a $75.4 million IPO. The firm is developing drug treatment candidates for solid tumors and other cancer conditions. Turnstone Biologics' major partners have terminated their collaboration agr...

2023-07-09 09:15:00 ET Summary Moderna is setting up operations in Shanghai to develop and manufacture mRNA products for the Chinese market, investing up to $1 billion. F-star Therapeutics has formed a collaboration with Takeda to develop Fcab domains for immuno-oncology targets, ...

2023-07-07 14:00:03 ET Summary Shares of diagnostics and drug discovery concern Adaptive Biotechnologies Corporation have crashed over 90% as the commercial-stage concern struggles with profitability. On the top line, the company’s clonoSEQ test volume increased 57% year-ov...